These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Uptake of Tc-99m monophosphate complexes in bone and myocardial necrosis in animals.
    Author: Kung HF, Ackerhalt R, Blau M.
    Journal: J Nucl Med; 1978 Sep; 19(9):1027-31. PubMed ID: 690703.
    Abstract:
    Bidentate monophosphates--phosphonoacetate (PAA), 2-phosphonoproprionate (PPA), 2-methyl-2-phosphonoproprionate (MPPA), and carbamyl phosphate (CAP)--which are pyrophosphate analogs, were successfully labeled with Sn(II)-reduced [99mTc] pertechnetate in high yield (greater than 95%). Biodistribution studies show that these Tc-99m-labeled monophosphates do localize in bone. At 2 hr after injection, Tc-99m CAP has average femur uptakes of 1.9% in rats and 2.9% in rabbits, which correspond to calculated total-bone uptakes of 38% and 58%, respectively. These are comparable with the femur uptakes for Tc-99m methylene diphosphonate (MDP), which are 1.8% in rats and 2.7% in rabbits. However, the blood clearance rate for Tc-99m CAP was slower than that observed for Tc-99m MDP making the former less desirable for use as a bone-scanning agent. The femur uptakes for Tc99m PAA are 0.9% in rats and 1.2% in rabbits, corresponding to 18% and 24% in total bone, respectively. The PAA derivatives PPA and MPPA have much lower bone uptake. Technetium-99m CAP also concentrates in necrotic myocardium in rats, in amounts comparable to Tc-99m pyrophosphate.
    [Abstract] [Full Text] [Related] [New Search]